Compare FTI & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTI | INSM |
|---|---|---|
| Founded | 1884 | 1988 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.8B | 22.4B |
| IPO Year | 2016 | 2000 |
| Metric | FTI | INSM |
|---|---|---|
| Price | $59.15 | $142.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 24 |
| Target Price | $76.45 | ★ $194.18 |
| AVG Volume (30 Days) | 2.7M | ★ 3.9M |
| Earning Date | 10-29-2026 | 10-29-2026 |
| Dividend Yield | ★ 0.33% | N/A |
| EPS Growth | ★ 20.42 | N/A |
| EPS | ★ 2.59 | N/A |
| Revenue | ★ $9,932,600,000.00 | N/A |
| Revenue This Year | $9.11 | $206.90 |
| Revenue Next Year | $5.42 | $60.68 |
| P/E Ratio | $23.67 | ★ N/A |
| Revenue Growth | ★ 9.35 | N/A |
| 52 Week Low | $43.34 | $90.39 |
| 52 Week High | $80.70 | $212.75 |
| Indicator | FTI | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 30.80 | 74.43 |
| Support Level | N/A | $135.73 |
| Resistance Level | $71.95 | $142.90 |
| Average True Range (ATR) | 2.38 | 7.04 |
| MACD | -0.39 | 3.18 |
| Stochastic Oscillator | 2.76 | 83.03 |
TechnipFMC PLC is the key provider of offshore oilfield services, offering integrated deep-water offshore oil and gas development solutions that span the full spectrum of subsea equipment and subsea construction services. The company also provides various pieces of surface equipment used with onshore oil and gas wells. TechnipFMC originated with the 2017 merger of Technip and FMC Technologies. Geographically it operates in Latin America generating the maximum revenue, then Europe and Central Asia, Africa, North America, Asia Pacific and Middle East.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.